GLP-1 Medications and Mental Health: What the Current Research Shows

Direct Answer

On January 13, 2026, the FDA requested that manufacturers remove the suicidal ideation and behavior warning from the labeling of Saxenda, Wegovy, and Zepbound. This followed a comprehensive review, including a meta-analysis of 91 placebo-controlled trials involving 107,910 patients, which found no increased risk of suicidal thoughts, suicidal behavior, or other psychiatric adverse events like anxiety, depression, irritability, or psychosis, compared to placebo.

How the FDA Reached This Conclusion

The review included both the large trial meta-analysis and a separate retrospective cohort study using FDA Sentinel System healthcare claims data, comparing new GLP-1 users against users of a different diabetes medication class (SGLT2 inhibitors) and finding no increased risk of intentional self-harm. The FDA concluded that the overall body of evidence does not support a causal relationship between GLP-1 medications and suicidal thoughts or behavior.

Where Scientific Discussion Continues

In the interest of giving a complete picture, it's worth noting that a separate systematic review and meta-analysis found continued scientific uncertainty in this area, citing wide prediction intervals across the smaller pool of available studies, and referenced pharmacovigilance database reports of suicidal ideation cases among GLP-1 users. Pharmacovigilance reports like these are spontaneous reports that flag possible signals for further investigation, they don't establish that a medication caused an outcome, which is exactly why the FDA's much larger, controlled trial-based review is the more authoritative source for evaluating actual risk. The FDA's January 2026 finding represents the most comprehensive and current assessment available.

Research Also Points to Potential Benefits

Separately from the safety question, research has explored whether GLP-1 medications might offer some mental health benefits. Animal studies have shown reduced anxiety-like behavior, and some human research suggests reduced anxiety incidence and lower suicidal ideation risk, though this evidence is described as mixed and preliminary. A completed clinical trial also found statistically significant improvements in mental health, eating disorder symptoms, and quality-of-life measures like sleep quality and pain interference over six months of GLP-1 treatment for obesity. This is an active, evolving research area, not a settled conclusion in either direction.

What Current Guidance Recommends

Even with the warning removal, the FDA continues to recommend that patients tell their healthcare provider about any new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior while taking a GLP-1 medication. This is standard, sensible practice for any medication, not a sign of ongoing specific concern about this drug class.

References

• FDA: Drug Safety Communication, Removal of Suicidal Behavior and Ideation Warning (January 13, 2026)
• Pharmacy Times: FDA Finds No Increased Suicide Risk With GLP-1 Medications
• PMC: Association of GLP-1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour, Systematic Review and Meta-Analysis
• LifeStance Health: GLP-1 Medications and Mental Health, Benefits Backed by Research

Related Resources

• GLP-1 Medication Library
• What Is Food Noise, and How Do GLP-1 Medications Quiet It?

Related Articles

• Should I Exercise While on a GLP-1 Medication?

Explore More

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Get Started

Download DietApp.com to track your medication and how you're feeling day to day, useful context for conversations with your provider.

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. The information on DietApp.com is intended for educational purposes only and does not constitute medical advice. Tell your healthcare provider about any new or worsening mood changes, suicidal thoughts, or unusual behavior while taking any medication. If you or someone you know is in crisis, call or text 988 to reach the Suicide and Crisis Lifeline, available 24 hours a day, 7 days a week.